Insulet Corporation (BMV:PODD)
Mexico · Delayed Price · Currency is MXN | Market Cap | 172.51B -61.8% |
| Revenue (ttm) | 53.35B +29.4% |
| Net Income | 6.56B +59.0% |
| EPS | 92.55 +59.4% |
| Shares Out | n/a |
| PE Ratio | 26.31 |
| Forward PE | 21.29 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7 |
| Open | 2,780.00 |
| Previous Close | 2,548.13 |
| Day's Range | 2,780.00 - 2,780.00 |
| 52-Week Range | 2,548.13 - 6,038.64 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Insulet
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controll... [Read more]
Financial Performance
In 2025, Insulet's revenue was $2.71 billion, an increase of 30.73% compared to the previous year's $2.07 billion. Earnings were $247.10 million, a decrease of -40.93%.
Financial numbers in USD Financial StatementsNews
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 31, 2026 in Insulet Corporation Lawsuit - PODD
Notice to Pension Funds, Asset Managers, and Fiduciaries Holding PODD: Institutional Portfolios Face Significant Exposure Following Two Omnipod Medical Device Corrections and Over $90 Per Share Declin...
Insulet to Participate in Wells Fargo 21st Annual Healthcare Conference
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will prese...
Insulet participates in a conference call with JPMorgan
JPMorgan holds a post 2Q earnings conference call on August 13 at 3 pm.
Contact Robbins LLP for Information About Leading the Lawsuit That Alleges Insulet Corporation Misled Investors Regarding the Safety and Reliability of its Insulin Delivery Products
SAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Insu...
Insulet Corporation Investors With Significant Losses Must Act By August 31, 2026
NEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds Insulet Corporation (“Insulet” or the “Company”) (NASDAQ: PODD) investors of the August 31, 2026 deadline to seek the role of le...
Insulet price target lowered to $175 from $248 at Baird
Baird analyst Jeff Johnson lowered the firm’s price target on Insulet (PODD) to $175 from $248 and keeps an Outperform rating on the shares. The firm updated its model following…
Insulet price target lowered to $180 from $190 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Insulet (PODD) to $180 from $190 and keeps a Buy rating on the shares.
Leerink downgrades Insulet to Market Perform, lowers target to $145
As previously reported, Leerink downgraded Insulet (PODD) to Market Perform from Outperform with a price target of $145, down from $247. Although Q2 U.S. and outside-U.S. revenue modestly exceed conse...
Insulet price target lowered to $144 from $294 at TD Cowen
TD Cowen lowered the firm’s price target on Insulet (PODD) to $144 from $294 and keeps a Hold rating on the shares. The firm said 2Q results were overshadowed by…
Insulet price target lowered to $185 from $250 at Benchmark
Benchmark lowered the firm’s price target on Insulet (PODD) to $185 from $250 and keeps a Buy rating on the shares.
Insulet price target lowered to $150 from $174 at UBS
UBS analyst Patrick Wood lowered the firm’s price target on Insulet (PODD) to $150 from $174 and keeps a Neutral rating on the shares.
Insulet price target lowered to $180 from $225 at Stifel
Stifel analyst Jonathan Block lowered the firm’s price target on Insulet (PODD) to $180 from $225 and keeps a Buy rating on the shares.
Insulet price target lowered to $175 from $200 at Bernstein
Bernstein lowered the firm’s price target on Insulet (PODD) to $175 from $200 and keeps an Outperform rating on the shares following quarterly results. While the quarter itself was strong,…
Insulet downgraded to Market Perform from Outperform at Leerink
Leerink analyst Mike Kratky downgraded Insulet (PODD) to Market Perform from Outperform with a $145 price target
Insulet price target lowered to $160 from $245 at RBC Capital
RBC Capital lowered the firm’s price target on Insulet (PODD) to $160 from $245 and keeps an Outperform rating on the shares. Insulet lowered its FY26 Omnipod growth outlook due…
Insulet price target lowered to $179 from $249 at Canaccord
Canaccord lowered the firm’s price target on Insulet (PODD) to $179 from $249 and keeps a Buy rating on the shares. The firm said Insulet delivered a Q2 revenue and…
Insulet downgraded to Neutral from Buy at BTIG
BTIG analyst Marie Thibault downgraded Insulet (PODD) to Neutral from Buy without a price target The company beat Q2 estimates but called out lower utilization and retention trends in the…
Insulet downgraded to Neutral from Overweight at JPMorgan
JPMorgan downgraded Insulet (PODD) to Neutral from Overweight with a price target of $152, down from $275. JPMorgan also removed the shares from its Analyst Focus List. Insulet’s slower new…
Insulet downgraded to Equal Weight from Overweight at Wells Fargo
Wells Fargo analyst Larry Biegelsen downgraded Insulet (PODD) to Equal Weight from Overweight with a price target of $144, down from $255, following the Q2 report. The company cut its…
Insulet downgraded to Hold from Buy at Truist
Truist downgraded Insulet (PODD) to Hold from Buy with a price target of $153, down from $210. The firm sees the company’s churn in type 2 diabetes and “soon-to-be intensifying”…
Oppenheimer calls Insulet outlook ‘huge surprise,’ downgrades shares
Oppenheimer downgraded Insulet (PODD) to Perform from Outperform without a price target following the Q2 report. Insulet lowered its fiscal 2026 U.S. growth to 17%-19% and its implied 2027 outlook…
Insulet downgraded to Perform from Outperform at Oppenheimer
Oppenheimer analyst Suraj Kalia downgraded Insulet (PODD) to Perform from Outperform.
Insulet price target lowered to $150 from $172 at Citi
Citi lowered the firm’s price target on Insulet (PODD) to $150 from $172 and keeps a Neutral rating on the shares post the Q2 report. The firm says the company’s…
This Medtech Beat Earnings Estimates. It's the Worst S&P 500 Stock Today.
Insulet lowers its full-year revenue growth outlook, even after earnings and revenue handily beat expectations.
Insulet Slides: Investor presentation
Insulet has posted slides in relation to its latest quarterly earnings report, which was published on August 5, 2026.